Androgen Receptor-Mediated Regulation of Intracellular Calcium in Human Airway Smooth Muscle Cells

Rama Satyanarayana Raju Kalidhindi a Rathnavali Katragadda a Kerri L. Beauchamp a Christina M. Pabelick b,c Y.S. Prakash b,c Venkatachalem Sathish a

a Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, USA, b Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA, c Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA

Key Words
Sex Difference • Sex Steroid • Testosterone • Airway • Asthma • Contractility

Abstract
Background/Aims: With the prevalence of asthma being greater in women, detrimental effects of female sex steroids have been explored, but potential protective effects of androgens are not established. Airway smooth muscle (ASM) is a key cell type in contractility and remodelling of asthma. There are no data on expression and functionality of androgen receptor (AR) in human ASM cells. Methods: We used primary human ASM cells from non-asthmatics vs. asthmatics to determine AR expression at baseline and with inflammation measured using Western blotting/qRT-PCR, and the role of AR in regulating intracellular Ca²⁺ ([Ca²⁺] i) measured using Fluo-3 loaded real time [Ca²⁺] i imaging. Results: We found that compared to females, baseline AR is greater in male ASM and increases with inflammation/asthma. Androgens, via AR, blunted TNFα or IL-13-induced enhancement of ASM [Ca²⁺] i in both males and females, with retained efficacy in asthmatics. AR effects involve reduced Ca²⁺ influx via L-type channels and store-operated Ca²⁺ entry, the latter by downregulating STIM1 and Orai1 and increasing TMEM66. Conclusion: Our data show AR expression is increased in female ASM with asthma, but has retained functionality that could be used to reduce [Ca²⁺] i towards alleviating airway hyperresponsiveness.

Introduction
Bronchial asthma is a leading cause of morbidity across the age spectrum, and involves increased airway inflammation, epithelial mucus secretion, airway hyperreactivity involving enhanced airway smooth muscle (ASM) contractility, and chronic airway remodelling,
latter a result of increased cell proliferation and fibrosis [1, 2]. Asthma in adults shows a sex difference where for example, in 2014, ~60% of the 3,651 deaths attributed to asthma occurred in women (American Lung Association) [3]. Amongst the general adult population, asthma prevalence is higher in women than men with distinctive changes in the prevalence and severity of asthma with age [4, 5]. Asthma increases steadily in both sexes from birth onwards to the early teenage years, but is significantly higher in males. From teenage years through midlife, prevalence decreases dramatically in males, but increases in females. With subsequent aging, prevalence increases in males and decreases in females, converging in late adulthood [4, 6]. These clinical data highlight the potential modulatory role of sex hormones on the prevalence and severity of asthma.

The effects of the sex steroids estrogen (E₂), progesterone (P) and testosterone (TES) in the context of asthma have been explored to varying extents in different elements of the bronchial airways (reviewed in [5, 7, 8]). One obvious point from studies done in different species (including humans), cell types (epithelium, ASM, fibroblasts, immune cells) and experimental interventions is that sex steroid effects in the airways are cell- and context-specific [5]. Thus, understanding sex steroid biology in the context of asthma and sex differences necessitates studies in specific cell types.

ASM is a major cell type in asthma given its importance to airway contraction and relaxation [5, 8-11] as well as airway remodeling [12-15]. Here, previous studies including our own have demonstrated an alleviating effect of female sex steroids particularly estrogens in regulation of ASM intracellular Ca²⁺ ([Ca²⁺]ᵢ) [16], proliferation and extracellular matrix (ECM) production [14]. While the focus on estrogens is appropriate, the effects on [Ca ²⁺]ᵢ or remodeling run counter to the greater incidence of asthma in women, raising the question of whether it should be important to also explore the effect of male sex steroids to better understand sex differences.

Androgens are known to regulate intracellular calcium [Ca²⁺]ᵢ levels and contractility of various smooth muscle types [16-22]. Androgens such as testosterone (TES) and Dihydro Testosterone (DHT- an active metabolite of TES) have been found to relax smooth muscle and non-genomically decrease Ca²⁺ influx through L-type calcium channels (LTCC), large-conductance Ca²⁺-activated potassium (BKCa) channels, store operated Ca²⁺ channels (SOCC) and myosin light chain (MLC) phosphorylation [17, 19, 23-27]. The relaxant effects of androgen agonists on tracheal smooth muscle cells in animal models of asthma have been previously explored, with biological actions of TES and DHT shown to be mediated by the high-affinity androgen receptor (AR), a member of the nuclear receptor superfamily, which in response to hormone regulates gene expression in target tissues [28-31], including AR expression itself [28]. Studies in airway tissues from different animal species (especially guinea pig) found that AR activation modulates LTCCs and SOCC [25] as well as modulation of IP₃ receptors [32], with effects being epithelium and potassium channel independent [33], and similar effects of Dehydroepiandrosterone (DHEA) in asthmatic guinea pig models [31]. In contrast, epithelium-dependent relaxation in rabbit trachea by TES has also been reported [26]. However, all of these studies, including the expression of AR and non-genomic effects of AR activation have been performed in animal models or cells, with no studies on AR expression in human airways or their mechanisms of action.

In this novel study, we explore the expression of AR in primary human ASM cells derived from non-asthmatic vs. asthmatic patients of both genders, and the modulatory effect of inflammatory cytokines. Furthermore, the genomic effect of AR activation on [Ca²⁺]ᵢ regulation is explored. We hypothesize that the AR expression is increased during asthma/ inflammation and AR activation downregulates [Ca²⁺]ᵢ in a genomic fashion, thus helping to blunt airway hyperresponsiveness (AHR).
Materials and Methods

Chemicals, drugs/inhibitors, antibodies

Cell culture reagents and other cell culture supplies including fetal bovine serum (FBS) and Dulbecco’s Modified Eagle’s Medium F-12 (DMEM/F12) were purchased from Invitrogen (Carlsbad, CA). Pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin-13 (IL-13) were purchased from Santa Cruz Biotechnology, Inc (Dallas, TX). Pharmacological modulators for AR, Testosterone (TES) and Flutamide were obtained from Tocris (Minneapolis, MN). CPA was procured from ChemCruz. Antibodies; Androgen Receptor Santa Cruz Biotechnology, Inc (Dallas, TX) and β-actin Applied Biological Materials, Inc (Richmond, BC). All other chemicals and supplies were from Sigma (St. Louis, MO) unless otherwise specified.

Human ASM cells

The technique for isolating human ASM cells has been previously described [18, 34, 35]. Third to sixth generation human bronchi were obtained from lung specimen’s incidental to patient thoracic surgery at Mayo Clinic for focal, non-infectious causes (typically lobectomies for focal cancers). Normal lung areas were identified with the help of a pathologist (protocol approved by Mayo Clinic Institutional Review Board). Samples were denuded of epithelium and ASM tissue enzymatically dissociated to generate cells for experiments (<5th passage). Cells were maintained under standard conditions of 37°C (5% CO₂, 95% air). Cells were serum starved for 24 h prior to experimentation.

Cell Treatments

Human ASM cells in T-75 flasks were trypsinized and mixed in 10% FBS (Charcoal Stripped) Growth medium (DMEM/F12 with 1% AbAm), counted and seeded ~10,000 cells/well into 8-well chamber slides. Cells were incubated overnight followed by serum deprivation (DMEM/F12 without FBS) for 24 h. ASM cells were treated with AR agonists Testosterone (TES, 10 nM) or 5-alpha-DiHydro Testosterone (5αDHT/DHT, 10 nM) with or without flutamide (AR antagonist) in serum free media. After 2 h of pre-incubation with respective treatment groups, cells were then exposed to TNFα (20 ng/ml) or IL-13 (50 ng/ml) for 24h. Serum free media alone served as vehicle. Similarly, ASM cells were grown on 100 mm petri plates and treated as above to collect lysates for protein or mRNA for western and qRT-PCR analysis respectively.

qRT-PCR Analysis

Cells were washed with RNA-grade DPBS, trypsinized and centrifuged. Total RNA was extracted using Quick-RNA™ MiniPrep kit (Zymo Research, Irvine, CA) following manufacturer’s protocol. cDNA was synthesized using OneScript cDNA Synthesis Kit using ~500-600ng of quantified RNA (Take3™ Micro volume plate, Synergy HTX, Biotek, USA) for each sample (Applied Biological Materials Inc, Richmond, BC, Canada). LightCycler 480 SYBR Green 1 Master PCR kit (Cat# 0470751601) protocol was followed using QuantStudio 3 RT-PCR system as per the manufacturer’s instructions. The following primers were used for RT-PCR analysis: AR (forward 5’-GCC TTG CTC TCT AGC CTC AA-3’, reverse 5’-GGT CGT CCA CGT GTA AGT TG-3’) and s16 (forward 5′-CAA TGG TCT CAT CAA GGT GAA CGG-3′, reverse 5′-CTG GAT AGC ATA AAT CTG GGC-3′). The fold changes in mRNA expression were calculated by normalization of cycle threshold [C(t)] value of target genes to reference gene s16 using the ΔΔCt method [14, 15, 36].

Western analysis

Previously described techniques were used [14, 37]. Briefly, cells were washed, sonicated in lysis buffer (Cell Signaling Technologies, Beverly, MA, USA) containing protease and phosphatase inhibitors, and resultant supernatants were assayed for total protein content using the DC Protein Assay kit (BioRad, Hercules, CA, USA). 30 µg equivalent protein from each lysate were loaded on 4-15% SDS-page and transferred onto 0.22 µm PVDF membranes. Non-specific binding was blocked using 5.0% bovine serum albumin (BSA) and the membranes were probed overnight at 4°C with specific primary antibodies of interest (Androgen receptor, STIM1, Orai-1 and TMEM66 with β-actin as a loading control). Blots were then incubated with LiCOR near-conjugated or HRP conjugated secondary antibodies. Membranes were scanned using LiCOR Odyssey CLX or developed on radiography films and densitometry analysis was performed using Image Studio version 5.2 software or Image J (NIH).
Real-time Intracellular Calcium \([\text{Ca}^{2+}]\) Imaging

After 24 hours of incubation with the respective treatments, drug solutions (media) were aspirated and human ASM cells were washed with freshly prepared HBSS (1X) buffer solution. Further, they were incubated with 4 \(\mu\)M Fluo-3 dye (prepared in HBSS solution) for 1 h at room temperature. Following an hour, the dye was aspirated, and cells were washed twice with HBSS buffer solution. The ASM cells were imaged at a 20X oil-magnification on GFP fluorescence (excitation 475-495 nm, and emission 520-560 nm) in the Biotek Lionheart FX automated live cell imaging system [16, 34, 38-40].

AR siRNA studies

Human ASM cells were cultured in 8-well plates or 100 mm plates to approximately 50% confluence. Transfection was achieved using 20 nM AR siRNA (Cat# SO-2685308G) and Lipofectamine 3000 transfection reagent (Invitrogen) in DMEM/F-12 and 5% FBS lacking antibiotics. Fresh growth medium was added after 6 h and cells were analyzed after 48 h. Negative Control siRNA (Cat# AM4611) was procured from Ambion. Efficacy and specificity of siRNA knockdown was verified using Western analysis. The effect of AR siRNA on \([\text{Ca}^{2+}]\) in the presence and absence of TNF\(\alpha\), IL-13 and Testosterone were analyzed as mentioned above.

Store Operated Calcium Entry (SOCE)

For SOCE imaging, cells were washed with HBSS (with 2.5 mM Ca\(^{2+}\)) and then loaded with 4 \(\mu\)M Fluo-3 AM dye for 1h at room temperature. The cells were then washed three times with 1X HBSS ("0" calcium) and proceeded with imaging in an Olympus FV-300 imaging station with shutter control system and CCD camera using a FITC filter. Solutions were added to the wells using a peristaltic pump system with a fixed flow rate. The overflowing solution was aspirated using a vacuum pump attached to the system. Initially HBSS without calcium was passed and for 2 min, followed by HBSS (without calcium) with 10 \(\mu\)M KCL for 4 min and HBSS (without calcium) with 10 \(\mu\)M KCL and 1 \(\mu\)M Nifedipine for 4 min. Images were captured every 10 seconds using Cell Sens software. The cells were then subjected to HBSS ("0" calcium) with 10 \(\mu\)M KCL, 1 \(\mu\)M Nifedipine and 10 \(\mu\)M CPA for 4 minutes, followed by introducing Ca\(^{2+}\) in the same solution for 2 minutes. During this phase, images were captured every second. Region of interest’s (ROI) were selected randomly from 5-10 cells and change in fluorescence intensity was recorded using Cell Sense software (Olympus Inc., USA) [38, 40].

Statistical analysis

Experiments were performed in human ASM cells from 3-5 patients (non-asthmatic males, non-asthmatic females, asthmatic males and asthmatic females). "n" values represent patient numbers for individual experiments. All the experiments were repeated at least two times for each patient sample. Data expressed as mean ± SEM. Statistical analysis was performed using individual one-way ANOVA or two-way ANOVA with Bonferroni post-hoc test where applicable. Statistical significance was tested at minimum of \(p<0.05\) level.

Results

AR expression in human ASM cells

Baseline mRNA expression of AR was significantly higher \((p<0.05)\) in male non-asthmatic human ASM cells compared to female non-asthmatic ASM cells. Western analysis of ASM cell lysates also indicated significantly higher \((p<0.01)\) AR expression in male non-asthmatics compared to female non-asthmatics. In asthmatic human ASM cells, AR mRNA and protein expression were significantly greater in both males \((p<0.05\) for mRNA and \(p<0.01\) for protein) and females \((p<0.05\) for mRNA and \(p<0.01\) for protein) compared to non-asthmatic human ASM cells (Fig. 1A and 1B). Notably, AR expression was markedly greater in female asthmatic ASM cells compared to non-asthmatics and the increase was comparable to that in males (Fig. 1A, B).
Effect of inflammation on AR expression in human ASM cells

In non-asthmatic human ASM cells of both males (p<0.001) and females (p<0.01), AR mRNA expression was significantly increased in the presence of TNFα (20 ng/ml) compared to vehicle, while no significant increase was observed in cells exposed to IL-13 (50 ng/ml). In addition, AR mRNA expression was significantly increased (p<0.001) in asthmatic females in the presence of TNFα, while no significant changes were observed in male asthmatics exposed to TNFα (Fig. 2A, B). IL-13 exposed asthmatic ASM cells did not show any significant
changes in AR mRNA expression. TNFα-induced increase in AR mRNA expression was more pronounced in female asthmatic human ASM (p<0.001) compared to males; whereas, in non-asthmatic human ASM cells AR mRNA expression was more in males (p<0.001) compared to females (p<0.01, Fig. 2A and 2B). Western analysis revealed a significant increase in AR expression in non-asthmatic males and females (p<0.001) exposed to TNFα. Interestingly, IL-13 exposed cells also showed a significant increase in AR protein in male non-asthmatics (p<0.001) and female non-asthmatics (p<0.01) compared to vehicle. However, in asthmatic ASM cells, only females showed significant increase in AR expression in the presence of TNFα (p<0.001) or IL-13 (p<0.05) compared to vehicle (Fig. 2C and 2D).

Effect of AR activation on [Ca²⁺]i regulation in human ASM cells

Imaging studies using Fluo-3 loaded human ASM cells showed a significant enhancement of histamine-elicited [Ca²⁺]i response following exposure to TNFα compared to vehicle in both non-asthmatics (p<0.001 for males and females) and asthmatics (p<0.001 for males and females). TNFα enhancement of [Ca²⁺]i tended higher in asthmatics compared to non-asthmatics. 24h exposure of TES (10 nM) did not show any significant effects on [Ca²⁺]i responses to histamine in either non-asthmatic or asthmatic ASM cells. However, both non-asthmatic and asthmatic ASM cells treated with TES followed by TNFα exposure showed a significant decrease (p<0.001 for males and p<0.01 for females in non-asthmatics and p<0.01 for males and p<0.001 for females in asthmatics) compared to TNFα alone. Here, the effects of TES were abrogated by flutamide (Fig. 3A and 3B), highlighting the role of AR activation. In addition, cells treated with DHT (10 nM) followed by TNFα exposure showed significant decrease in [Ca²⁺]i response in both males and females for non-asthmatics (p<0.001 in males and p<0.01 in females) and asthmatics (p<0.001 in males and females) compared to TNFα alone (Fig. 3C and 3D). Here, the effect of DHT on reducing [Ca²⁺]i response induced by TNFα was more prominent in asthmatics compared to non-asthmatics. DHT effect was inhibited in the presence of flutamide. Human ASM cells treated with DHT alone did not show any notable changes in [Ca²⁺]i compared to vehicle.
Exposure to IL-13 resulted in a significant increase (p<0.001 in males and females) in \([\text{Ca}^{2+}]_i\) responses to histamine for both non-asthmatics and asthmatic human ASM cells. Treatment with TES blunted the effects of IL-13 in non-asthmatic and asthmatic ASM cells (p<0.001 both male and female, Fig. 4A and 4B). In the presence of IL-13, DHT treated ASM cells showed significant reduction in \([\text{Ca}^{2+}]_i\) response (p<0.001, Fig. 4C and 4D) compared to IL-13 alone. The inhibitory effects of TES and DHT on \([\text{Ca}^{2+}]_i\) in IL-13 exposed cells was not observed in the presence of flutamide.

**Mechanisms of AR-mediated effects on \([\text{Ca}^{2+}]_i\) regulation**

Removal of extracellular Ca\(^{2+}\) still resulted in histamine-induced \([\text{Ca}^{2+}]_i\) responses that were enhanced by TNFα in both non-asthmatic (p<0.001) and asthmatic (p<0.001) ASM cells. TNFα induced increase in \([\text{Ca}^{2+}]_i\) was significantly downregulated by TES in non-asthmatic (p<0.001) and asthmatic (p<0.001) ASM cells. Similarly, even in zero extracellular Ca\(^{2+}\), IL-13 enhanced \([\text{Ca}^{2+}]_i\) responses to histamine in non-asthmatic (p<0.001) and asthmatic (p<0.001) ASM cells: effects significantly inhibited by TES in non-asthmatic (p<0.05 for males and p<0.01 for females) and asthmatic (p<0.05 for males and females) cells. TES effects were not observed in the presence of flutamide (Fig. 5A and 5B).

To confirm the role of ARs, we used siRNA to knockdown AR expression in ASM cells. siRNA knockdown efficiency was confirmed using Western analysis (~70% reduction; Fig. 6A, B). AR siRNA transfected cells were exposed to TES (10 nM) for 2h and further treated with TNFα or IL-13 for 24h followed by real-time \([\text{Ca}^{2+}]_i\) imaging. AR siRNA transfected ASM cells continued to show a significant increase in \([\text{Ca}^{2+}]_i\) response to histamine following exposure to TNFα (p<0.001) and IL-13 (p<0.05) compared to negative siRNA; however, TES did not have any significant effects following with AR siRNA (Fig. 6B).

Non-asthmatic ASM cells from males exposed to nifedipine (15 min) showed significant (p<0.05) decrease in \([\text{Ca}^{2+}]_i\) responses to histamine compared to vehicle (no nifedipine). Nifedipine did not eliminate TNFα enhancement of \([\text{Ca}^{2+}]_i\), which was significantly reduced (p<0.01) in cells treated with TES. Similar findings were observed in the case of IL-13 exposed human ASM cells, where a significant increase (p<0.05) in \([\text{Ca}^{2+}]_i\) response was observed, which was significantly reversed (p<0.01) in TES treated cells (Fig. 6C). TES treated cells
in the presence of Nifedipine did not show any significant changes in \([\text{Ca}^{2+}]\) response to histamine compared to Nifedipine alone treated cells indicating the effect is partly through LTCC.

**Fig. 5.** Effect of TES on regulating \([\text{Ca}^{2+}]\) in human ASM cells in zero extracellular calcium environment during TNFα and IL-13 exposure. A) Effect of TES on regulating \([\text{Ca}^{2+}]\) in non-asthmatic human ASM cells (male and female) and B) Effect of TES on regulating \([\text{Ca}^{2+}]\) in asthmatic human ASM cells (male and female). TNFα and IL-13 significantly increased the \([\text{Ca}^{2+}]\) response to histamine in non-asthmatic and asthmatic human ASM cells compared to vehicle. This increase in \([\text{Ca}^{2+}]\) was significantly inhibited in ASM cells treated with TES, while ASM cells exposed to Flutamide before TES administration did not show any significant downregulation of TNFα/IL-13 induced increase in \([\text{Ca}^{2+}]\). **p<0.001 vs. vehicle, *p<0.05, **p<0.01 and ***p<0.001 vs. cytokines. Data expressed as mean ± SEM. n=3 patients each.

**Fig. 6.** Effect of TES on regulating \([\text{Ca}^{2+}]\) during pro-inflammatory cytokine exposure (TNFα and IL-13) in AR siRNA knockdown ASM cells and ASM cells exposed to Nifedipine (L-type calcium channel inhibitor). A) Confirmation of AR knockdown using siRNA by western analysis. B) Representative blot showing downregulated AR with siRNA knockdown. C) Effect of TES on regulating \([\text{Ca}^{2+}]\) in AR siRNA knockdown non-asthmatic human ASM cells in response to histamine. D) Effect of TES on regulating \([\text{Ca}^{2+}]\) response to histamine in the presence of Nifedipine in non-asthmatic human ASM cells. $p<0.05$ vs. vehicle, $#p<0.05$ and $##p<0.01$ vs. neg. siRNA/vehicle (+Nifedipine) and **p<0.01 vs cytokines (+ Nifedipine). Data expressed as mean ± SEM. n=3 for siRNA and n=5 for Nifedipine studies (non-asthmatic males).
Both non-asthmatic and asthmatic ASM cells demonstrated robust SOCC (as also previously shown [35, 38-40]. Non-asthmatic cells from males exposed to TNFα showed significant increase (p<0.001) in SOCE compared to vehicle. While TES did not influence the amplitude of SOCE per se, TES significantly reduced SOCE in the presence of TNFα and IL-13 (p<0.001). IL-13 exposed cells showed a significant increase (p<0.01) in SOCE compared to vehicle, which was significantly decreased (p<0.05) by TES (Fig. 7A and 7B). In addition, Western analysis showed significant increase in the expression of STIM1 (p<0.01, Fig. 7C) and Orai1 (p<0.001, Fig. 7D) with exposure to TNFα, which was significantly downregulated (p<0.01 for STIM1 and p<0.001 for Orai1) by pre-treatment with TES. Furthermore, TNFα exposed human ASM cells showed significant decrease in the expression of TMEM66 (p<0.001, Fig. 7E), but TMEM66 was significantly increased (p<0.01) by pre-treatment with TES. IL-13 exposed cells did not show any significant changes in the expression of STIM1 and Orai1, but TMEM66 was significantly decreased (p<0.01) compared to vehicle: an effect blunted by TES (p<0.05).
Discussion

Asthma is increasing in prevalence, with substantial morbidity [5, 12, 41, 42]. The etiology of asthma involves inflammation, remodeling and AHR with an important role for ASM [5, 9, 10, 12, 43-47]. Evidence from clinical studies suggest sex differences in the prevalence of asthma, and a potential role of sex steroids in the pathophysiology [4-6, 48-52]. However, the protective vs. detrimental roles of sex steroids is less clear. Here, much of the focus has been on female sex steroids, including effects on ASM [5, 14-16, 18, 37, 53-56], but the relative importance of male sex steroids has been less examined. In this study, we explored AR-mediated effects in the context of [Ca\textsuperscript{2+}]\textsubscript{i} regulation and its modulation by disease (asthma) and inflammatory cytokines, finding that TES reduces ASM [Ca\textsuperscript{2+}]\textsubscript{i} responses by inhibiting Ca\textsuperscript{2+} influx and expression of relevant proteins, and is effective even in the presence of inflammation.

In animal models, significant differences between males and females with regards to fetal lung development have been reported such as delayed maturation and less surfactant in males: differences that extend to adulthood in the context of disease where for example, greater allergic airway responses are observed in female mice as well as in castrated male mice, as well as greater AHR with cholinergic stimulation in male mice [15, 17, 20, 21, 30, 31, 50]. While these data are consistent with epidemiological data suggesting women are more susceptible to asthma compared to men, they also are in contrast to a number of studies showing “protective” effects of female sex steroids in the context of ASM [Ca\textsuperscript{2+}], and contractility [16], remodeling [14, 57] and AHR [15]. Regardless, these and other data also suggest a protective role of the male sex hormone testosterone [50-52, 58]. Our data are consistent in this regard, and explore potential mechanisms of TES action.

Testosterone elicits its action through AR both genomically and non-genomically [28, 59, 60]. Several studies have reported non-genomic effects of TES on ASM but have relied on animal models or cells derived from non-human species [17, 19, 26, 32]. There is no information on the expression profile of AR in human ASM, especially during inflammation, or on effects of long-term activation of AR on ASM in the context of [Ca\textsuperscript{2+}]\textsubscript{homeostasis}. Here, it is important to recognize that AR expression is not limited to airways of females, raising the question of whether or not AR functionality exists in both sexes and if they are quantitatively or qualitatively different. In this study, we explored sex-specific differential expression of AR in both non-asthmatic and asthmatic primary human ASM cells in the presence/absence of pro-inflammatory cytokines (TNF\textalpha and IL-13). Our studies indicate a baseline difference in the expression of AR in ASM of females (low) vs. males (high) which in many ways is to be expected, given the usual low level of androgen ligand in females and the known regulation of AR expression by receptor stimulation [28, 61], thus resulting in reduced receptor levels in the absence of stimulation. An interesting finding however was a significant increase in AR expression in asthmatic ASM of both sexes, which likely occurs in females independent of changes in androgen levels. The effects of inflammation per se is suggested by the findings of increased AR expression in both non-asthmatic and asthmatic primary human ASM cells with cytokine exposure. With inflammation known to enhance contractility [38, 39], increased AR expression permits continued bronchodilatory effects of TES. What is less clear is the functional significance of such increased AR expression in female airways where TES or other androgens are likely to be still at very low levels.

Our studies show that TES, via AR, reduce [Ca\textsuperscript{2+}]\textsubscript{i} responses to agonist in both male and female ASM, highlighting functionality of the AR in both sexes. Interestingly, consistent with upregulated AR in both males and females, TES continued to reduce [Ca\textsuperscript{2+}], even in asthmatic ASM or with TNF\textalpha or IL-13 exposure, suggesting maintained functionality that would be of physiological significance at least in males. However, it is also interesting to note that the decrease in [Ca\textsuperscript{2+}], by TES or DHT was more pronounced in female asthmatics (again consistent with the greater change in AR in this sex). This surprising finding suggests a potentially novel approach to inducing bronchodilation in females by targeting the AR,
especially if done by local administration to the airways to minimize systemic androgenic effects in women.

The likely genomic effects of TES following extended exposure appear to target \([\text{Ca}^{2+}]_i\) regulatory mechanisms that are known to be increased in the context of asthma or cytokine exposure: LTCC, STIM1 and Orai1 [38-40, 62]. These \([\text{Ca}^{2+}]_i\) influx mechanisms are also involved in mediating TES effects on \([\text{Ca}^{2+}]_i\), as suggested by the effects of inhibitors such as nifedipine. Earlier studies suggest, TES inhibits LTCC non-genomically [62]. However, limited data in other cell types suggest TES actually increases LTCC [63]. Thus TES effects on this pathway may be cell-type dependent. Furthermore, \([\text{Ca}^{2+}]_i\), studies performed in zero extracellular calcium especially in the presence of TNFα or IL-13 show significant effects of TES/DHT suggesting a role for sarcoplasmic reticulum \([\text{Ca}^{2+}]_i\) release pathways such as the IP3 or RyR receptors that are known to be important in ASM \([\text{Ca}^{2+}]_i\) regulation [11, 38, 40, 64, 65]. Here, limited evidence does show that TES directly binds to IP3R and modifies its function in ASM [32].

Exploration of SOCE showed increased influx via this pathway following TNFα and to a lesser extent IL-13 exposure. TNFα and IL-13 have been shown to increase SOCE activity by increasing expression of the regulatory STIM1 protein and the Orai1 channel as well as downregulating TMEM66 in human ASM cells [18, 40, 64]. TNFα induced enhancement of SOCE was blunted by TES as was expression of STIM1 and Orai1 with concordant increase in TMEM66 that is involved in downregulating SOCE.

**Conclusion**

In conclusion, AR is expressed and is functional in ASM of both males and females, with a surprising greater increase in female ASM in asthmatics or with inflammatotry cytokine exposure. AR remains functional in disease, and its activation leads to decreased \([\text{Ca}^{2+}]_i\) via both inhibited \([\text{Ca}^{2+}]_i\) influx and reduced intracellular \([\text{Ca}^{2+}]_i\) release. Thus AR activation may be a viable and interesting approach to inducing bronchodilation in both sexes.

**Acknowledgements**

This study was supported by NIH Grants R01-HL123494 and R01-HL123494-02S1 (Venkatachalem), R01-HL088029 (Prakash), R01-HL142061 (Pabelick, Prakash) ND EPSCoR with NSF#1354466 and NDSU RCA.

Authors would like to thank Dr. Jagadish Loganathan and Dr. Nilesh Sudhakar Ambhore, Department of Pharmaceutical Sciences, NDSU for providing technical support in completion of this study.

**Disclosure Statement**

The authors of this manuscript declare no competing interests.

**References**


